Abstract 883P
Background
Mandibular bone resection is indicated in case of bone invasion or close contact with the tumor. The microvascular bone free flap (MBFP) is the reconstruction of choice. Despite a higher risk of complications, it allows oral rehabilitation. However, many patients do not benefit from it. We sought to assess the rate of non-rehabilitated patients and the reasons why.
Methods
This multicenter study was carried out in 6 centers in France. Patients were included if treated between January 2017 and January 2022 for head and neck carcinoma with MBFP. Patients who had relapsed or died were excluded. Included patients completed a telephone questionnaire.
Results
Of the 175 identified patients, 104 patients were finally included. Median follow-up since initial surgery was 26 months (min 18-max 60 months). MBFP consisted of a fibular free flap in 83% of cases, a scapular free flap in 16% of cases and an iliac crest free flap in 1% of cases. 61 patients (59%) had no oral rehabilitation. 17% of these patients had never been informed of the possibilities of oral rehabilitation, and 20% of these patients had never met any oral rehabilitation specialist. 22% of patients had an unsuccessful attempt at oral rehabilitation (removable prosthesis or implant-supported prosthesis). Of the 43 rehabilitated patients, 81% had a removable prosthesis and 19% an implant-supported prosthesis. Neither the number of osteotomies, nor the complexity of the reconstruction, nor the pre- or post-operative history of radiotherapy, nor the use of cutting guides were statistically associated with oral rehabilitation in this series. Only the presence of an oral rehabilitation specialist in the center had a significant influence on the rehabilitation rate (p=0.004), irrespective of the surgeon's specialty.
Conclusions
This is the first multicenter study to evaluate the rate of oral rehabilitation after free bone flap reconstruction for malignancy. Only 41% of patients benefited from rehabilitation. Regardless of the complexity of the reconstruction, the only factor influencing oral rehabilitation was the presence of an oral rehabilitation specialist in the center.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
890P - Stereotactic body radiation therapy combined with chemotherapy and tislelizumab in metastatic nasopharyngeal carcinoma: A prospective, single-arm, phase II study
Presenter: Tongxin Liu
Session: Poster session 02
891P - Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer: The POINT study
Presenter: Cristina Gurizzan
Session: Poster session 02
892P - Camrelizumab plus dalpiciclib in anti-PD-1 refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Xi Ding
Session: Poster session 02
894P - AXEL: AXitinib-avELumab combination in recurrent or metastatic (RM) nasopharyngeal cancer (NPC)
Presenter: Edwin Hui
Session: Poster session 02
895P - Cost effectiveness of stereotactic ablative radiotherapy (SABR) alone in comparison with systemic treatment and SABR in oligometastatic head and neck cancer in the GORTEC 2014-04 OMET randomized phase II study
Presenter: Juliette Thariat
Session: Poster session 02
896P - Day of the week of chemotherapy (CT) during concurrent chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC)
Presenter: Camilla Hoff
Session: Poster session 02
897P - Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma
Presenter: Jinling Yuan
Session: Poster session 02
898P - Real-world overall survival (OS) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in Asia: A literature review
Presenter: Darren Wan-Teck Lim
Session: Poster session 02
899P - Safety and efficacy of a novel CAR-T cell therapy (BRG01) targeting the Epstein-Barr Virus envelope glycoprotein in advanced metastatic nasopharyngeal cancer patients
Presenter: Li Zhang
Session: Poster session 02